Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Cardium Therapeutics Inc. (CRXM) had Normalized Pre-Tax Income of $-1.25M for the most recently reported fiscal year, ending 2020-12-31.
| Income Statement Financials | |
-- |
|
$-0.52M |
|
-- |
|
-- |
|
$1.26M |
|
$-1.26M |
|
$0.61M |
|
$-0.65M |
|
|
Normalized Pre-Tax Income |
$-1.25M |
$-0.65M |
|
$-0.65M |
|
$-0.65M |
|
$-1.25M |
|
$-1.26M |
|
$-1.26M |
|
24.12M |
|
24.12M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$0.41M |
|
$0.00M |
|
$0.16M |
|
$0.57M |
|
$5.03M |
|
$0.03M |
|
$0.11M |
|
$5.14M |
|
$-4.57M |
|
$-4.57M |
|
$-4.57M |
|
40.33M |
|
| Cash Flow Statement Financials | |
$-1.13M |
|
$-0.00M |
|
$1.52M |
|
$0.00M |
|
$0.39M |
|
$0.39M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.08 |
|
-- |
|
-- |
|
-0.01 |
|
-0.13 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.14M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
14.26% |
|
14.26% |
|
-114.92% |
|
14.35% |
|
$-0.11 |
|
$-0.05 |
|
$-0.05 |
|